Seattle Genetics, Inc.
) recently presented interim results from a phase I study which
is evaluating ASG-5ME for the treatment of metastatic pancreatic
ductal adenocarcinoma (PDA).
Seattle Genetics is developing ASG-5ME, an antibody-drug
conjugate (ADC) which targets the SLC44A4 antigen, for the
treatment of solid tumors. The candidate is being developed in
collaboration with Agensys, Inc., an affiliate of Tokyo-based
Astellas Pharma Inc.
The trial is being conducted to evaluate the safety and
activity along with identifying the maximum tolerated dose (MTD)
of ASG-5ME in patients suffering from metastatic PDA.
Approximately 35 patients with metastatic PDA and a median age of
63 were administered doses ranging from 0.3 milligrams per
kilogram (mg/kg) to 1.5 mg/kg administered weekly for three of
every four weeks. Data from the study, apart from providing
preliminary evidence for antitumor activity, revealed that the
candidate was well tolerated.
We note that Seattle Genetics is also evaluating ASG-5ME in
the prostate and gastric cancer indications. Seattle Genetics
focuses on the development and commercialization of monoclonal
antibody-based therapies for cancer.
We remind investors that Seattle Genetics' leading drug,
Adcetris, is currently approved in the US for the treatment of
patients with Hodgkin lymphoma after failure of autologous stem
cell transplant (ASCT) or after failure of at least two prior
multi-agent chemotherapy regimens in patients, who are not
suitable for ASCT and the treatment of sALCL in
treatment-experienced patients. Adcetris is approved in the EU as
Seattle Genetics carries a Zacks Rank #3 (Hold). Pharma
stocks, which currently appear to be more attractive include
). Both companies carry a Zacks Rank #1 (Strong Buy).
(ALPMY): ETF Research Reports
SEATTLE GENETIC (SGEN): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
To read this article on Zacks.com click here.